Wee-Lee Yeo
Impact in
- Oncology top 5%
- Lung Cancer Research Studies
- Colorectal Cancer Treatments and Studies
- HER2/EGFR in Cancer Research
-
- Lung Cancer Treatments and Mutations
- Brain Metastases and Treatment
- Lung Cancer Diagnosis and Treatment
Papers in
- Oncology 5
- Cancer Treatment and Pharmacology 2
- Colorectal Cancer Treatments and Studies 2
- Lung Cancer Research Studies 2
-
- Lung Cancer Treatments and Mutations 4
- Lung Cancer Diagnosis and Treatment 1
- Co-authors
- Daniel B. Costa (4 shared papers)Susumu Kobayashi (4 shared papers)Keith D. Wilner (1 shared paper)Weiwei Tan (1 shared paper)Shuchi S. Pandya (1 shared paper)Zhongzhou Shen (1 shared paper)Boon-Cher Goh (4 shared papers)Mark G. Kris (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)Pharmacogenetics and Genomics (2 papers)Investigational New Drugs (1 paper)Journal of Thoracic Oncology (1 paper)Physiotherapy (1 paper)
- Partner nations
- SingaporeUnited StatesJapan
In The Last Decade
Wee-Lee Yeo
11 papers receiving 644 citations
Hit Papers
Peers
Comparison fields: 5 of 58
- Oncology 494
- Pulmonary and Respiratory Medicine 507
- Cancer Research 76
- Genetics 41
- Molecular Biology 223
Countries citing papers authored by Wee-Lee Yeo
This map shows the geographic impact of Wee-Lee Yeo's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wee-Lee Yeo with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wee-Lee Yeo more than expected).
Fields of papers citing papers by Wee-Lee Yeo
This network shows the impact of papers produced by Wee-Lee Yeo. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wee-Lee Yeo. The network helps show where Wee-Lee Yeo may publish in the future.
Co-authors
The 25 scholars most cited alongside Wee-Lee Yeo, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | CSF Concentration of the Anaplastic Lymphoma Kinase Inhibitor Crizotinib Hit paper breakdown → | 2011 | 474 |
| 2 | 2010 | 66 | |
| 3 | 2009 | 35 | |
| 4 | 2011 | 32 | |
| 5 | 2009 | 16 | |
| 6 | Gemcitabine and platinum pathway pharmacogenetics in Asian breast cancer patients. | 2012 | 14 |
| 7 | 2014 | 6 | |
| 8 | 2012 | 6 | |
| 9 | 2012 | 4 | |
| 10 | Misleading ECG recordings. | 2011 | 3 |
| 11 | 2015 | 1 |
About Wee-Lee Yeo
Wee-Lee Yeo is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Cancer Research, Molecular Biology and Hematology, having authored 11 papers that have together received 657 indexed citations. Recurring topics across this work include Lung Cancer Treatments and Mutations (4 papers), Cancer Genomics and Diagnostics (3 papers), Cancer Treatment and Pharmacology (2 papers), Colorectal Cancer Treatments and Studies (2 papers), Lung Cancer Research Studies (2 papers), Lung Cancer Diagnosis and Treatment (1 paper), Breast Cancer Treatment Studies (1 paper) and Histone Deacetylase Inhibitors Research (1 paper). The work is most often cited by research in Oncology (494 citations), Pulmonary and Respiratory Medicine (507 citations), Cancer Research (76 citations), Genetics (41 citations) and Molecular Biology (223 citations). Wee-Lee Yeo has collaborated with scholars based in Singapore, United States and Japan. Frequent co-authors include Daniel B. Costa, Susumu Kobayashi, Keith D. Wilner, Weiwei Tan, Shuchi S. Pandya, Zhongzhou Shen, Boon-Cher Goh, Mark G. Kris, William Pao and Gregory J. Riely. Their work appears in journals such as Journal of Clinical Oncology, Pharmacogenetics and Genomics, Investigational New Drugs, Journal of Thoracic Oncology and Physiotherapy.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.